Clinical trials: psoriasis
Plaque Psoriasis
Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)
The purpose of this study is to determine if calcipotriene/bethamethasone can safely and effectively manage the occurence of LMB (mild localized breakthrough) in patients recieving efalizumab (Raptiva) for moderate to severe…
- Trial name
- NCT00608777
- Testing
- Calcipotriene/betamethasone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Derm Research, PLLC
Psoriasis
Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study
The purpose of this study is to determine the safety and efficacy of the use of the combination therapy adalimumab (ADA) every other week (EOW) with methotrexate (MTX) in suboptimal responders to ADA monotherapy.
- Trial name
- CLEAR (NCT02196701)
- Testing
- Adalimumab, Methotrexate
- Volunteers
- 46 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)
- Trial name
- NCT05855967
- Testing
- Ixekizumab
- Where
- 14 sites in India
- Volunteers
- 250 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
Plaque Psoriasis Efficacy and Safety With Secukinumab
To demonstrate in the patient pool of PASI 90 responders at Week 24 that secukinumab 300 mg s.c. when administered at a longer dosing interval is non-inferior to secukinumab 300 mg s.c.
- Trial name
- OPTIMISE (NCT02409667)
- Testing
- Secukinumab
- Where
- 200 sites in Austria, Belgium and 22 more
- Volunteers
- 16,487 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
A healthy subject, 2-way cross-over study to evaluate the bioequivalence of a single dose of Brodalumab vs. two doses of Brodalumab
- Trial name
- NCT02173392
- Testing
- Brodalumab
- Where
- 6 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Scalp Psoriasis
Maintenance Effect of Clobex Shampoo on Participants With Moderate to Severe Scalp Psoriasis
The objective of the study was to assess the maintenance effect on scalp psoriasis of Clobex® Shampoo 0.05% when used twice weekly.
- Trial name
- NCT00400725
- Where
- Canada
- Volunteers
- 288 people
- Sponsor
- Galderma R&D
Psoriatic Arthritis
Diet Interventions in Psoriatic Arthritis
The purpose of this study is to learn whether changing diet impacts psoriatic arthritis (PsA).
- Trial name
- DIPSA (NCT04180904)
- Testing
- Diet 1, Diet 2
- Where
- 2 sites in United States, Canada
- Volunteers
- 92 people
- Sponsor
- University of Pennsylvania
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE SURE (NCT03412747)
- Testing
- Bimekizumab, Adalimumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 478 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
LEO 90105 Ointment in Japanese Subjects With Psoriasis
The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis…
- Trial name
- NCT01422434
- Testing
- LEO 90105 = calcipotriol + betamethasone dipropionate, Dovonex® = calcipotriol, Rinderon® - DP = betamethasone dipropionate
- Where
- Japan
- Volunteers
- 676 people
- Sponsor
- LEO Pharma
Psoriasis
Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
The purpose of this study was to assess efficacy and safety data of secukinumab in Japanese subjects with generalized pustular psoriasis (GPP).
- Trial name
- NCT01952015
- Testing
- Secukinumab
- Where
- 10 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Safety Study of Mirikizumab (LY3074828)
The main purpose of this study is to evaluate the safety of the study drug known as mirikizumab. The study will investigate how the body processes the study drug and how the drug affects the body.
- Trial name
- NCT01947933
- Testing
- Mirikizumab- IV, Mirikizumab - SC
- Where
- 2 sites in Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis, Psoriasis
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
- Conditions
- Plaque Psoriasis, Psoriasis, Skin Diseases
- Trial name
- IMPACT-PS (NCT03832738)
- Testing
- JTE-451 Tablets
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Psoriasis
Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab
This study will evaluate the efficacy of etanercept in patients with plaque psoriasis who have lost a satisfactory response to adalimumab.
- Trial name
- NCT01543204
- Testing
- Etanercept
- Where
- 47 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Amgen
Psoriasis
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab…
- Trial name
- NCT00195676
- Testing
- adalimumab
- Where
- 104 sites in United States, Austria and 8 more
- Volunteers
- 1,469 people
- Sponsor
- Abbott
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
- Trial name
- BE BRIGHT (NCT03598790)
- Testing
- Bimekizumab
- Where
- 189 sites in United States, Australia and 11 more
- Volunteers
- 1,353 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Plaque psoriasis is a chronic relapsing inflammatory skin disease that is characterized by keratinocyte hyper-proliferation and epidermal hyperplasia.
- Trial name
- NCT04316585
- Testing
- GSK2982772
- Where
- 9 sites in Canada, Poland
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Psoriasis, Psoriatic Arthritis
Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice
This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis.
- Trial name
- PREPARE (NCT01147874)
- Testing
- lab draws and imaging
- Where
- 45 sites in United States, Belgium and 5 more
- Volunteers
- 1,013 people
- Sponsor
- Pfizer
Palmo-plantar Psoriasis
Apremilast in Palmo-Plantar Psoriasis
This study will compare the safety and efficacy of Apremilast 30mg to placebo in subjects with moderate to severe plaque psoriasis involving palms and/or soles.
- Trial name
- NCT02400749
- Testing
- Apremilast
- Where
- 11 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Innovaderm Research Inc.
Ankylosing Spondylitis, Psoriatic Arthritis
Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis
This 12-month postmarketing observational study (PMOS) was a prospective, single-arm, multicenter, multi-country study, with follow-up visits at 3, 6, 9, and 12 months after the initial baseline visit.
- Trial name
- NCT01474876
- Volunteers
- 566 people
- Sponsor
- AbbVie (prior sponsor, Abbott)